Currently, there are 39.17M common shares owned by the public and among those 36.09M shares have been available to trade.
The company’s stock has a 5-day price change of 24.13% and 45.96% over the past three months. SILK shares are trading 119.23% year to date (YTD), with the 12-month market performance down to -17.86% lower. It has a 12-month low price of $6.08 and touched a high of $33.78 over the same period. SILK has an average intraday trading volume of 1.18 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.18%, 29.06%, and 76.72% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Silk Road Medical Inc (NASDAQ: SILK) shares accounts for 102.85% of the company’s 39.17M shares outstanding.
It has a market capitalization of $1.07B and a beta (3y monthly) value of 1.52. The earnings-per-share (ttm) stands at -$1.37. Price movements for the stock have been influenced by the stock’s volatility, which stands at 0.59% over the week and 4.06% over the month.
Earnings per share for the fiscal year are expected to increase by 4.10%, and 5.21% over the next financial year. EPS should grow at an annualized rate of 1.60% over the next five years, compared to -3.21% over the past 5-year period.
Looking at the support for the SILK, a number of firms have released research notes about the stock. Argus stated their Buy rating for the stock in a research note on March 07, 2024, with the firm’s price target at $24. Stifel coverage for the Silk Road Medical Inc (SILK) stock in a research note released on January 19, 2024 offered a Buy rating with a price target of $20. Stifel on their part issued Hold rating on October 11, 2023.
